Last updated: 2026-09-04 20:00:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
GRI Bio, Inc. (GRI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.89, with a market capitalisation of $4.37M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.36 to $80.36. This page covers its latest market performance, valuation, price trends and company information.
$4.37M | |
$2.34 | |
$2,248,100.40 | |
$1.36 | |
$2.29 | |
7.00M | |
-- | |
-- | |
$80.36 | |
$1.36 | |
-- | |
-- |
GRI Bio, Inc. (GRI) is trading at $2.89 in after-hours trading as of 2026-09-04 19:59:00, up 25.98% ($0.59) from the regular-session close of $2.29.
After-hours trading shows how investors are pricing GRI after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, GRI Bio, Inc. (GRI) moved from $1.93 to $2.89, representing a gain of 49.53% ($0.96).
The stock traded between $2.25 and $3.34 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 1.27 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1.9%
GRI is currently trading at $2.89, placing it 1.9% of the way from its 52-week low of $1.36 to its 52-week high of $80.36. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 5 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of GRI Bio, Inc. (GRI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.